OIPN Assessment Tool Segmentation for Neuropathy Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current patient-reported assessment tools for chemotherapy-induced peripheral neuropathy, such as OIPN, lack sensitivity and specificity, leading to low positive response rates and floor effects, which complicates the monitoring of neuropathy severity and intervention measures.
Innovation Solution
A patient-reported assessment tool, CIPNIA-OS, with a main scale and subscale, grades symptoms based on frequency, location, duration, and influence, using a scoring formula (S=T1−tmax+tmax×T2) to enhance the accuracy and sensitivity of OIPN assessment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If universal questionnaires are used for CIPN assessment, then broad applicability is achieved, but sensitivity and specificity are reduced
Solution Approach 1:
The assessment tool is segmented into a main scale with 17 symptom items and a subscale with 3 core items (location, duration, influence). This segmentation allows the tool to capture both broad symptomatology and specific critical features of OIPN, resolving the contradiction between universal applicability and measurement precision by organizing assessment content at different levels of detail.
Solution Approach 2:
The subscale focuses on local quality by specifically assessing the three most critical dimensions of OIPN (location, duration, influence) with weighted scoring. This local emphasis on key symptoms while maintaining a comprehensive main scale enables the tool to achieve both broad coverage and high sensitivity for detecting meaningful changes in neuropathy severity.
2Adaptability or versatility
If comprehensive symptom coverage is included, then overall assessment capability is improved, but floor effect increases
Solution Approach 1:
The scoring system uses parameter changes by implementing a weighted scoring formula where the subscale items (location, duration, influence) carry higher weights than individual main scale items. This parameter differentiation ensures that comprehensive symptom coverage is maintained while preventing floor effect through meaningful score differentiation that reflects true symptom severity and change.
3Measurement precision
If detailed symptom grading is implemented, then assessment accuracy is improved, but complexity of the tool increases
Solution Approach 1:
The tool segments detailed assessment into two parts: a comprehensive main scale with standardized 4-level grading for 17 symptoms, and a focused subscale with 3 items. This segmentation maintains assessment accuracy through detailed grading while managing complexity by organizing content hierarchically and using a structured scoring formula that systematically combines results from both sections.
Data Source
AI summary
The present invention discloses a patient-reported assessment tool dedicated for assessment of oxaliplatin-induced peripheral neuropathy (OIPN), comprising a main scale, a subscale and a scoring formula. The assessment contents of the main scale contain symptoms of body organs and are graded based on patient's subjective feelings about the frequency of the neuropathy, corresponding to relative scores. The assessment contents of the subscale contain location, duration and influence of the most severe symptom. The present invention effectively improves the accuracy and sensitivity of CIPN assessment through the targeted application range design and the maximum item weight addition, and improves the clinical reference value of CIPN assessment by elaborating the description of OIPN symptoms and integrating the features of several validated assessment tools, and provides reference for the development of CIPN assessment tools.